Illumina, Inc. (ETR:ILU)

Market Cap	12.20B
Revenue (ttm)	4.00B
Net Income (ttm)	-891.81M
Shares Out	n/a
EPS (ttm)	-5.61
PE Ratio	n/a
Forward PE	20.41
Dividend	2.89 (3.80%)
Ex-Dividend Date	Jun 25, 2024

Volume	62
Average Volume	268
Open	77.05
Previous Close	78.39
Day's Range	77.05 - 78.05
52-Week Range	62.00 - 150.56
Beta	1.13
RSI	65.21
Earnings Date	Aug 7, 2025

About Illumina

Illumina, Inc. provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa. The company offers sequencing- and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. It also provides whole...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1998
• Employees: 9,030
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: ILU

Financial Performance

In 2024, Illumina's revenue was $4.37 billion, a decrease of -2.93% compared to the previous year's $4.50 billion. Losses were -$1.22 billion, 5.34% more than in 2023.

Financial numbers in USD